+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

O

Actively Recruiting

Healthy Volunteer

Researchers are conducting a non-interventional, observational study to understand the long-term use of dupilumab in treating eosinophilic esophagitis EoE among patients aged 12 years and older in Germany. The study aims to describe patients medical history, socio-demographic and disease characteristics, related conditions, prior therapies, and the real-world patterns of dupilumab treatment. It also seeks to assess long-term effectiveness and safety of dupilumab, along with its impact on patients quality of life over two years. Participants in this study are those receiving dupilumab for EoE in routine clinical settings without any treatment intervention from the study team. The observational period for each participant is planned to last approximately two years, during which data on dupilumab use and safety will be collected continuously. This includes tracking treatment details, symptom changes, and any adverse events as reported by physicians and patients. Throughout the study, participants will have their medical, socio-demographic, and disease data analyzed at baseline. Follow-up assessments will record changes in endoscopic scores, esophageal biopsy results, clinical symptoms, food intake behavior, and various quality of life and symptom scales at multiple time points over two years. Hospitalization and sick leave data related to EoE will also be monitored. Safety data will be collected throughout the treatment period to better understand dupilumabs long-term use in real-world practice.

Age: 12Years +All Genders
15 locations
O

Actively Recruiting

Researchers are conducting a prospective, observational study to assess asthma control, health-related quality of life HRQL, lung function, and medication use in patients with severe eosinophilic asthma who are treated with benralizumab under routine care in Germany. The study aims to observe how these patients manage their asthma over time and how their treatment impacts their daily lives and health status. Participants receive benralizumab as part of their standard care, with no experimental treatment assigned by the study. The study lasts up to 52 weeks and monitors changes in asthma control using tools like the Asthma Control Test ACT and the Asthma Impairment and Risk Questionnaire AIRQ. Health-related quality of life is measured at baseline and follow-ups using the mini Asthma Quality of Life Questionnaire miniAQLQ. Patients also keep a weekly diary of their asthma medication intake, either on paper or electronically, to track any changes. Throughout the study, participants will have assessments at various time points up to one year after starting benralizumab. These include questionnaires on asthma control and quality of life, lung function tests, and biomarker measurements such as eosinophil levels and exhaled nitric oxide. Researchers analyze changes in medication doses and asthma symptoms, while patients regularly report their experiences. The study focuses on real-world outcomes without altering prescribed treatments, aiming to provide insights into the effects of benralizumab in everyday clinical practice.

Age: 18Years - 120YearsAll Genders
41 locations
O

Actively Recruiting

Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.

Age: 18Years +All Genders
90 locations
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
O

Actively Recruiting

This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.

Age: 18Years +All Genders
93 locations
A

Actively Recruiting

Researchers are evaluating whether adding Acalabrutinib to the standard R-miniCHOP chemotherapy can improve progression-free survival in older adults with untreated diffuse large B-cell lymphoma DLBCL. This phase 3, randomized trial compares outcomes of patients receiving R-miniCHOP alone with those receiving R-miniCHOP plus Acalabrutinib. The study focuses on individuals 61 years and older who are ineligible for full-dose R-CHOP treatment. Participants will be randomly assigned to one of two groups one receiving 6 cycles of R-miniCHOP plus 2 doses of Rituximab, and the other receiving the same regimen combined with Acalabrutinib taken orally twice daily for 8 cycles. The chemotherapy cycles are repeated every 3 weeks, and the study is open-label, meaning both participants and researchers know which treatment is given. During the trial, participants will undergo regular assessments to monitor disease progression, survival, remission rates, and adverse events for up to 5 years. Researchers will evaluate blood tests, physical exams, and other health parameters to measure outcomes such as progression-free survival, overall survival, event-free survival, and treatment safety. The study aims to provide detailed information on long-term effects and treatment tolerability in this older patient population.

Age: 61Years +All GendersPhase 3
17 locations
S

Actively Recruiting

Researchers are investigating the real-world use of encorafenib plus binimetinib for patients with unresectable advanced or metastatic melanoma that has a BRAF V600 mutation. This observational study focuses on documenting treatment effects, quality of life, safety, and tolerability after these drugs became commercially available in Germany, Austria, and Switzerland. The study specifically looks at patients treated in the first and second line settings after prior checkpoint inhibitor therapy. The study observes patients who are treated with encorafenib plus binimetinib according to the approved product guidelines. Participants may have started this treatment up to six months before joining the study or may begin treatment soon after enrollment. The study tracks treatment details, effectiveness, side effects, and patient-reported outcomes over a median treatment duration of about 12 months, with a total observation period of up to 90 months. Participants will be followed through regular documentation of their disease and treatment progress, including patient and disease profiles, treatment sequences, adverse events, and quality of life assessments using questionnaires. The main outcome measured is progression-free survival at 12 months after treatment start. Researchers will also evaluate treatment duration, interruptions, dose intensity, and physician satisfaction. Long-term safety and prognostic factors will be monitored throughout the observation period until study completion in September 2027.

Age: 18Years +All Genders
59 locations
S

Actively Recruiting

Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.

Age: 18Years +All Genders
70 locations
E

Actively Recruiting

This research aims to collect treatment data on the new Plasma Filter PX2 used in therapeutic plasma exchange TPE for patients with autoimmune diseases. The study evaluates the plasma filters performance when combined with the multiFiltrate and multiFiltratePRO devices during TPE treatments. The single-group design reflects everyday clinical practice and seeks to contribute empirical evidence on the devices use without altering patients treatment plans. Participants will receive TPE treatments using the investigational Plasma Filter PX2 alongside the multiFiltrate or multiFiltratePRO devices. Treatments are conducted according to clinical standards established at each center and prescribed by the treating physician. The study does not define a fixed treatment schedule and includes documentation of up to ten TPE treatments per participant. During the study, researchers will collect detailed information about the TPE treatments, including therapy parameters over an average period of about seven weeks depending on individual indications and treatment frequency. Participants will be monitored for treatment data collection, and safety assessments like pregnancy testing will be conducted as needed. The studys total duration spans from treatment documentation through to study completion, supporting a comprehensive evaluation of the Plasma Filter PX2.

Age: 18Years +All GendersPhase Not Applicable
7 locations
P

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and quality of life for combining Abemaciclib with either an Aromatase Inhibitor or Fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase IV trial focuses on both pre- and postmenopausal patients receiving first-line treatment. A digital health app called CANKADO will be used to track side effects and patient-reported outcomes daily, alongside standard documentation. The study also aims to explore biomarkers to better understand treatment responses and resistance. Participants will receive either Abemaciclib combined with an Aromatase Inhibitor Anastrozole, Letrozole, or Exemestane taken orally twice daily plus daily Aromatase Inhibitor tablets every 24 hours in 28-day cycles, or Abemaciclib with Fulvestrant which is given as an injection on specific days within 28-day cycles. The two treatment groups are experimental and non-randomized, with no masking. The trial includes monitoring for side effects and quality of life throughout treatment. During the study, participants will regularly report side effects and global health status using questionnaires at multiple time points up to 24 months, including specialized breast cancer quality of life modules. Researchers will assess progression-free survival up to 48 months, as well as adverse events, hospitalizations, clinical benefit rate, overall survival, and tumor response. The use of the CANKADO app for side effect reporting is strongly recommended but not mandatory. Participants will be followed for safety and outcomes throughout the trial duration.

Age: 18Years +FEMALEPhase 4
54 locations

1-10 of 26

1